In a Twist, Venture-Backed Biotech Formation Bio Raises Its Own Investment Fund

Formation Bio, a privately held drug company, needed cash to acquire additional medicines and chose not to raise another venture round. Instead, it raised a $600 million fund, according to the Wall Street Journal. The approach is unusual for a venture-backed biotechnology company, which typically relies on successive equity rounds to finance drug development.

The company's strategy centers on acquiring drug compounds and advancing them through clinical trials. Formation houses each drug program in a newly formed company, or newco, a structure that isolates individual assets while allowing the parent to deploy capital across a pipeline. The fund is intended to secure more drug candidates for that pipeline.

The Wall Street Journal characterized the move as a twist on conventional biotech financing, given the high risk and capital intensity of drug development. The primary source does not disclose the fund's investors, fee terms, or specific acquisition targets.